US Patents With Foreign Priority to Patent: 20157963
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-005 | May 5, 2026 | RX | Yes | Yes | 11,318,191 | ⤷ Start Trial | Y | METHOD OF TREATING TYPE 2 DIABETES | |||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-005 | May 5, 2026 | RX | Yes | Yes | 11,318,191 | ⤷ Start Trial | Y | REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE | |||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-006 | May 5, 2026 | RX | Yes | Yes | 11,318,191 | ⤷ Start Trial | Y | METHOD OF TREATING TYPE 2 DIABETES | |||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-006 | May 5, 2026 | RX | Yes | Yes | 11,318,191 | ⤷ Start Trial | Y | REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
